Rebecca McCrery, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Axonics, Inc. at 41.5% of the total. Reporting peaked in 2019 at $16,997 and has fallen 97.6% since, to $406 in 2025. Among urology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $216.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$29K
- Astellas Pharma US Inc$9K
- Medtronic$8K
- Bluewind Medical$7K
- Urovant Sciences Inc$7K
- Caldera Medical, Inc$4K
- plus $7K from 31 others
Across 204 payments — averaging $3024.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bluewind Medical$287K
- Axonics, Inc.$166K
- Coloplast$63K
- Provepharm Inc.$54K
- Medtronic$27K
- Boston Scientific$20K
What the payments were for
- Consulting fees$28,82141%
- Speaking & faculty fees$25,59036%
- Travel & lodging$8,02011%
- Food & beverage$8,03611%
- Education$3400%
- Gifts$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 99 | $29,424 |
| Astellas Pharma US Inc | 23 | $8,717 |
| Medtronic(2 entities) | 35 | $7,966 |
| Bluewind Medical | 12 | $6,919 |
| Urovant Sciences Inc | 18 | $6,843 |
| Caldera Medical, Inc | 21 | $4,435 |
| Boston Scientific | 7 | $3,005 |
| AbbVie(2 entities) | 29 | $1,096 |
| Palette Life Sciences, Inc. | 2 | $537 |
| Sumitomo Pharma America, Inc. | 30 | $522 |
| Coloplast | 4 | $390 |
| BD | 1 | $158 |
| AMAG Pharmaceuticals, Inc. | 3 | $140 |
| Valencia Technologies Corporation | 2 | $125 |
| Myovant Sciences Inc. | 6 | $90 |
| Bayer | 4 | $62 |
| Foundation Medicine, Inc. | 3 | $59 |
| Johnson & Johnson(2 entities) | 3 | $52 |
| Dendreon Pharmaceuticals LLC | 3 | $45 |
| Merck | 2 | $38 |
| Amgen | 2 | $32 |
| Therapeuticsmd, Inc. | 2 | $29 |
| Myriad Genetic Laboratories, Inc. | 2 | $28 |
| KARL Storz Endoscopy-america | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Immunitybio, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Conmed Corporation | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
| Medline Industries LP | 1 | $13 |
| Blue Earth Diagnostics | 1 | $13 |
| Urogen Pharma, Inc. | 1 | $13 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $12 |
| Mayne Pharma Commercial LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,941 in reported general payments places this provider in the 95th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 370 | $272,765 |
| MyrbetriqMirabegron | 305 | $195,375 |
| Estradiol | 361 | $24,947 |
| PremarinEstrogens, Conjugated | 22 | $9,519 |
| ImvexxyEstradiol | 25 | $8,217 |
| Mirabegron ErMirabegron | 12 | $7,582 |
| Solifenacin Succinate | 98 | $3,145 |
| Trospium Chloride | 54 | $2,804 |
| Methenamine Hippurate | 52 | $2,615 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 100 | $2,593 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 26 | $1,854 |
| NitrofurantoinNitrofurantoin Macrocrystal | 47 | $1,613 |
| Trimethoprim | 30 | $1,524 |
| Trospium Chloride ErTrospium Chloride | 12 | $1,201 |
| Clobetasol Propionate | 22 | $640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $522 | $272,765370 claims |
| Astellas Pharma US IncMyrbetriq | $8,717 | $195,375305 claims |
| Therapeuticsmd, Inc.Imvexxy | $29 | $8,21725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 urology providers in Nebraska.
Other urology in Omaha
- John BishayOmaha$138K
- Judson DaviesOmaha$67K
- Stefanie BolteOmaha$59K
- Michael FeloneyOmaha$29K
- Andrew TrainerOmaha$12K
- Stephen LeslieOmaha$12K
- Jon MortonOmaha$11K
- Brett HillOmaha$11K
- John HorganOmaha$10K
- Larry SirefOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.